Nomenclature of Quantities and Units in Thrombosis and Haemostasis (Recommendation 1993)

Chairman of the SSC Nomenclature Project and Past-Chairman of the SSC:; Chairs and co-chairs of the SSC's scientific subcommittees:; Ad hoc consultants:Chairman of the SSC:Past-Chairman of the ISTH:Chairman of the ISTH:Executive Director of ISTH and SSC:; IUPAC Commission on Quantities and Units in Clinical Chemistry and IFCC Committee on Quantities and Units:

doi:10.1055/s-0038-1642446

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1994; 71(03): 375-394
DOI: 10.1055/s-0038-1642446

Scientific and Standardization Committee Communications

Schattauer GmbH Stuttgart

Nomenclature of Quantities and Units in Thrombosis and Haemostasis (Recommendation 1993)

A Collaborative Project of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH/SSC) and the Commission/Committee on Quantities and Units (in Clinical Chemistry) of the International Union of Pure and Applied Chemistry-International Federation of Clinical Chemistry (IUPAC-IFCC/CQU(CC))

Chairman of the SSC Nomenclature Project and Past-Chairman of the SSC:

Chairs and co-chairs of the SSC's scientific subcommittees:

(

U Abildgaard

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

A M H P van den Besselaar

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

K J Clementson

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

B Dahlbäck

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

T Exner

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

C W Francis

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

P Gaffney

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

H Grainick

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

L W Hoyer

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

G J Johnson

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

C Kasper

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

D Lane

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

H R Lijnen

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

J M Lusher

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

P M Mannucci

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

L Poller

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

S I Rapaport

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

H Salto

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

K Stocker

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

,

D Thomas

¹The Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ, Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ, of Bern, Switzerland; and Dept, for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept,, Westmead Hospital, Syndney, Australia; and Dept, of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NiH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital. Los Angeles, California, USA; and Dept, of Haematology, Charing Cross and Westminster Hospital School of Med., London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med, Ctr., Univ. California, USA; and 1st Dept, of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom

)

Ad hoc consultants:

(

T W Barrowcliffe

²NIBSC, Hertfordshire, United Kingdom; and Cardiovascular Res. Institute, Maastricht, The Netherlands; and Dept, Clin, Biochem., Univ. Hospital of Copenhagen, Denmark; and George Washington University School of Medicine, Washington, DC, USA; and Hopital de Bicetre, France; and International Headquarters of ISTH, UNC Med. School, Chapel Hill, North Carolina, USA; and Dept. Clin. Chem,, Frederiksberg Hospital, Copenhagen, Denmark; and Dept, of Clin, Biochem., Univ. Hospital of Copenhagen, Denmark

,

C S Thorsen Hemker

²NIBSC, Hertfordshire, United Kingdom; and Cardiovascular Res. Institute, Maastricht, The Netherlands; and Dept, Clin, Biochem., Univ. Hospital of Copenhagen, Denmark; and George Washington University School of Medicine, Washington, DC, USA; and Hopital de Bicetre, France; and International Headquarters of ISTH, UNC Med. School, Chapel Hill, North Carolina, USA; and Dept. Clin. Chem,, Frederiksberg Hospital, Copenhagen, Denmark; and Dept, of Clin, Biochem., Univ. Hospital of Copenhagen, Denmark

,

D Aronson

²NIBSC, Hertfordshire, United Kingdom; and Cardiovascular Res. Institute, Maastricht, The Netherlands; and Dept, Clin, Biochem., Univ. Hospital of Copenhagen, Denmark; and George Washington University School of Medicine, Washington, DC, USA; and Hopital de Bicetre, France; and International Headquarters of ISTH, UNC Med. School, Chapel Hill, North Carolina, USA; and Dept. Clin. Chem,, Frederiksberg Hospital, Copenhagen, Denmark; and Dept, of Clin, Biochem., Univ. Hospital of Copenhagen, Denmark

,

K G Mann

²NIBSC, Hertfordshire, United Kingdom; and Cardiovascular Res. Institute, Maastricht, The Netherlands; and Dept, Clin, Biochem., Univ. Hospital of Copenhagen, Denmark; and George Washington University School of Medicine, Washington, DC, USA; and Hopital de Bicetre, France; and International Headquarters of ISTH, UNC Med. School, Chapel Hill, North Carolina, USA; and Dept. Clin. Chem,, Frederiksberg Hospital, Copenhagen, Denmark; and Dept, of Clin, Biochem., Univ. Hospital of Copenhagen, Denmark

,

Dominique Meyer

²NIBSC, Hertfordshire, United Kingdom; and Cardiovascular Res. Institute, Maastricht, The Netherlands; and Dept, Clin, Biochem., Univ. Hospital of Copenhagen, Denmark; and George Washington University School of Medicine, Washington, DC, USA; and Hopital de Bicetre, France; and International Headquarters of ISTH, UNC Med. School, Chapel Hill, North Carolina, USA; and Dept. Clin. Chem,, Frederiksberg Hospital, Copenhagen, Denmark; and Dept, of Clin, Biochem., Univ. Hospital of Copenhagen, Denmark

,

H R Roberts

²NIBSC, Hertfordshire, United Kingdom; and Cardiovascular Res. Institute, Maastricht, The Netherlands; and Dept, Clin, Biochem., Univ. Hospital of Copenhagen, Denmark; and George Washington University School of Medicine, Washington, DC, USA; and Hopital de Bicetre, France; and International Headquarters of ISTH, UNC Med. School, Chapel Hill, North Carolina, USA; and Dept. Clin. Chem,, Frederiksberg Hospital, Copenhagen, Denmark; and Dept, of Clin, Biochem., Univ. Hospital of Copenhagen, Denmark

)

IUPAC Commission on Quantities and Units in Clinical Chemistry and IFCC Committee on Quantities and Units:

Abstract

PDF Download

PDF (2367 kb)

References

References
1 Dybkaer R, Jprgensen K. Measurement, value and scale. Scand J Clin Lab Invest 49 Suppl 194: 69-76 1989;
2 International Union of Pure and Applied Chemistry and International Federation of Clinical Chemistry. Commission/Committee on Quantities and Units (in Clinical Chemistry). A proposal for a IUPAC-IFCC Recommendation. Quantities and Units in Clinical Laboratory Sciences. Mail ballot 1994-01.
3 Twelfth International Congress of Anatomists in London, 1985. Nomina Anatomica, 6th ed. Prepared by the International Anatomical Nomenclature Committee. London: Churchill Livingstone, 1989.
4 WHO (World Health Organization). The SI for the Health Professions. Prepared at the request of the Thirtieth World Health Assembly. Geneva: WHO, 1977.